Related Experiment Video
Updated: Jul 30, 2026
02:26
Intracranial Pharmacotherapy and Pain Assays in Rodents
Published on: April 9, 2019
Rizatriptan: pharmacological differences from sumatriptan and clinical results.
C R Lines1, K A McCarroll, W H Visser
1Merck Research Laboratories, West Point, PA, USA. chris_lines@merck.com
Current Medical Research and Opinion
|December 5, 2002
Summary
Rizatriptan offers faster and more effective migraine relief compared to sumatriptan, demonstrating superior outcomes in clinical trials. Both medications are well-tolerated, with similar mild side effects in patients without coronary artery disease.
Area of Science:
- Neurology
- Pharmacology
- Clinical Trials
Background:
- Rizatriptan and sumatriptan are selective 5-HT(1B/1D) receptor agonists used for acute migraine treatment.
- Oral rizatriptan exhibits faster absorption and higher bioavailability than oral sumatriptan.
Purpose of the Study:
- To compare the efficacy and safety of rizatriptan and sumatriptan in treating moderate to severe migraine attacks.
- To evaluate pharmacological advantages of rizatriptan translating into clinical benefits.
Main Methods:
- Randomized, double-blind, placebo-controlled clinical trials were conducted.
- Direct comparisons of oral rizatriptan (10 mg) versus sumatriptan (50 mg and 100 mg) were performed.
- Efficacy endpoints included time to pain relief, pain-free status, symptom resolution, patient satisfaction, and sustained response.
Main Results:
- Rizatriptan 10 mg demonstrated superiority over sumatriptan in achieving pain relief within 2 hours.
- A higher percentage of patients treated with rizatriptan 10 mg were pain-free at 2 hours compared to sumatriptan.
- Rizatriptan showed further advantages in sustained pain relief and overall symptom resolution.
Conclusions:
- Rizatriptan provides a faster onset of action and better overall response for acute migraine treatment compared to sumatriptan.
- Both rizatriptan and sumatriptan were well-tolerated in clinical trials, with common side effects including dizziness and drowsiness.
- Rizatriptan's pharmacological profile translates into significant clinical advantages for migraine sufferers.
Related Concept Videos
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...